Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Precaution Statements to Be Revised for Ketoprofen-Based OTC Drugs
November 1, 2010
- Takeda Sets Up Global Business Development Organization
November 1, 2010
- PMDA to Have Fewer Active Officials Dispatched from Korosho
November 1, 2010
- Daiichi Sankyo Healthcare Voluntarily Recalls Skin Cream
November 1, 2010
- PhRMA to Include Its Demand in US-Japan Talks for Regulatory Reform
October 25, 2010
- NICE Recommends Aricept for Mild AD
October 25, 2010
- Applications for Accreditation of Foreign Manufacturers Simplified
October 25, 2010
- Large Differences in Participation in Multinational Clinical Trials
October 25, 2010
- NDA Review Period Shortening in Japan: Mr Narita
October 25, 2010
- Indacaterol Significantly Improves Breathlessness: Novartis
October 25, 2010
- Korosho Requires Revisions of Package Inserts for Topical Ketoprofen
October 25, 2010
- 1st Gov't-Industry Meeting Held to Ensure Stable Supply of Mo-99
October 25, 2010
- Sales of Ethical Drugs Up 2.5% in August: Crecon Report
October 25, 2010
- Eli Lilly Japan to Target Orthopedic Surgeons in Promoting Forteo
October 25, 2010
- Continued Sales of Ketoprofen Products Should Be Permitted: CDFS
October 25, 2010
- Allermist Improves Ophthalmic Allergic Symptoms: Prof. Kurono
October 25, 2010
- CSO Market to Grow at 14.4% in FY2010 and Onward: MIC Research
October 25, 2010
- Original Itraconazole Product Shows Inter-Lot Differences
October 25, 2010
- 2 Kohdo-iryo Recommended for Use under Health Insurance Programs
October 25, 2010
- Price Settlement Rate 17.9% as of September at NPhA Members
October 25, 2010
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…